BOK Financial’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

BOK Financial’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25	Closed	-$2.27K	–	1199
2023 Q1	$2.27K	Buy	+25	New	+$1.47K	﹤0.01%	1109
2021 Q1	$2.02M	Buy	+20,220	New	+$2.36M	0.04%	385

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BOK Financial's RETA Position: Q2 2023 in Review

BOK Financial sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 25 shares — an estimated $2.27K sold.

BOK Financial first reported a position in RETA in Q1 2021 and held it in 2 quarters. The position peaked at $2.02M in Q1 2021. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

BOK Financial reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
BOK Financial sold 25 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $2.27K.
BOK Financial first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2021 and held it in 2 quarters.
BOK Financial's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.02M in Q1 2021.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on BOK Financial's 13F filing for Q2 2023, filed 21 Aug 2023.